SAN CARLOS, Calif., Oct 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nektar Therapeutics (Nasdaq: NKTR) President and CEO Howard W. Robin is scheduled to present at the upcoming Natixis Bleichroeder Second Annual Hidden Gems Conference in New York at the Waldorf-Astoria Hotel on Monday, October 13, 2008 at 2:30 p.m. ET.
The presentation will be accessible via Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 27, 2008.
About Nektar
Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled eight approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.
CONTACT:
Stephan Herrera
Nektar Therapeutics
1-415-488-7699
sherrera@nektar.com
SOURCE Nektar Therapeutics
http://www.nektar.com
Copyright (C) 2008 PR Newswire. All rights reserved
News Provided by COMTEX